Sagent Pharmaceuticals CEO Sees Big Market Opportunity For His Firm

By Staff and Wire Reports

Tuesday, 24 July 2012 12:50

In an exclusive video interview with healthcare analyst Avik Roy, Sagent Pharmaceuticals' (NASDAQ:SGNT) President and CEO Jeff Yordon says his specialty pharmaceutical company that develops, manufactures, sources and markets pharmaceutical products is drafting unique contracts with its customers.

In addition, he reveals that his firm is actively pursuing some M&A targets.

Flash Player 9 or higher is required to view the chart
Click here to download Flash Player now

"We believe right now that there’s a lot of companies out there who have a product or two and have built infrastructure around the capabilities of introducing those products," said Yordon. "We think a lot of the product is never going to achieve what they need to achieve. If we were to take product like that into our model, not have 150 people basically selling this to physicians instead using our relationships with GPOs and our relationships with physicians, even though the overall revenue wouldn’t be as high, the margin would be fantastic. These would be winners for us whereas some of the companies which will go unnamed they’re not going to probably be able to achieve. "

"We’re also looking at products less than a hundred million that are with major pharma companies that these would be considered very small products for them and we’re starting to actively begin to talk to those companies about divesting those type of products."

Sagent Pharmaceuticals was founded in 2006 by Yordon, with a mission to deliver an extensive portfolio of quality injectable products and fulfilling the evolving needs of the patients.

Watch the full video interview:

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites

Newsletter